Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04552704 · ClinicalTrials.gov registry record · Phase 1
CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study
A Phase 1 study, sponsored by Tianhong Li.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04552704: Clinical Trial Phase 1 study, sponsored by Tianhong Li.
NCT04552704 is a Phase 1 study that was terminated before completion, run by Tianhong Li. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04552704, a Phase 1 study, was terminated before completion, sponsored by Tianhong Li.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase I/II trial investigates the side effects and how well CD24Fc works in treating immune related adverse events in patients with solid tumors that have spread to other places in the body (advanced). CD24Fc may prevent autoimmune reactions due to the tissue damage induced by cancer treatment. CD24Fc binds to injured cell components and prevents inflammatory responses. CD24Fc also acts to turn off the immune system after it has been activated ("immune checkpoint"). Adding CD24Fc to standard treatment may shorten the recovery time and reduce the severity of side effects from immunotherapy.
Primary Outcome
Number of Participants with New Adverse Event (AE) of Grade \>= 3 (Phase I)
Interventions
- DRUG Placebo Administration
- BIOLOGICAL CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-10-30 |
| Est. Completion | 2022-01-26 |
| Phase | Phase 1 |
Why NCT04552704 stopped before completion
NCT04552704 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Administration is the first listed.
NCT04552704 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04552704 about?
NCT04552704 is a clinical study titled "CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study". This phase I/II trial investigates the side effects and how well CD24Fc works in treating immune related adverse events in patients with solid tumors that have spread to other places in the body (advanced). CD24Fc may prevent autoimmune reactions due to the tissue damage induced by cancer treatment....
What is the current status of trial NCT04552704?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2020-10-30. Estimated completion is 2022-01-26.
What interventions are being tested in trial NCT04552704?
The interventions under investigation include: Placebo Administration (DRUG), CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc (BIOLOGICAL).
Who is sponsoring clinical trial NCT04552704?
This trial is sponsored by Tianhong Li, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04552704's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI